Kura Oncology, Inc. and Mirati Therapeutics, Inc. announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). Under the terms of the agreement, Kura will sponsor the Phase 1 study of KO-2806 and adagrasib in patients with KRASG12C-mutated NSCLC. Mirati will supply Kura with adagrasib for the study.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.7 USD | -4.87% | -3.26% | +42.56% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.56% | 1.66B | |
+18.83% | 125B | |
+13.74% | 108B | |
-7.48% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-14.09% | 16.37B | |
+1.68% | 13.58B | |
+27.67% | 11.66B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology, Inc. and Mirati Therapeutics, Inc. Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASG12C-Mutated NSCLC